OTC SPERMICIDE TRIALS EVALUATING STD PROTECTIVE BENEFITS
This article was originally published in The Tan Sheet
OTC SPERMICIDE TRIALS EVALUATING STD PROTECTIVE BENEFITS should look at four specific endpoints in their design: human immunodeficiency virus (HIV) seroconversion, herpes infection transmission, papilloma infection transmission, and hepatitis seroconversion, FDA Division of Antiviral Drug Products Director David Feigal, MD, told a National Institutes of Health workshop on contraceptive efficacy and sexually transmitted disease prevention on April 7.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC